Portions of this Exhibit 10.30 have been omitted based upon
a request for confidential treatment. This Exhibit 10.30, including the non-public information, has been filed separately with
the Securities and Exchange Commission. “[*]” designates portions of this
document that have been redacted pursuant to the request for confidential treatment filed with the Securities and Exchange Commission.


 


Exhibit 10.30


 


PREFERRED PROVIDER AGREEMENT


 


The Preferred Provider Agreement (“PPA”
or “Agreement”) is made and entered into this 29th day of July, 2010 (“Effective Date”), by
and between Pharmasset, Inc., its subsidiaries and their affiliates, (collectively referred to herein as “Pharmasset”),
and Bioanalytical Systems, Inc. (and all of its affiliates, including its BAS Evansville, Inc., Bioanalytical Systems, Ltd., and
BASi Northwest Laboratory sites), West Lafayette, Indiana (collectively referred to herein as “BASi”).


 


WHEREAS, Pharmasset desires to use the
services of BASi for toxicology studies, pharmaceutical analyses and bioanalytical services (the “Services”), as needed
by Pharmasset;


 


WHEREAS, BASi wishes to be designated a
“preferred provider” of Pharmasset, and Pharmasset wishes to so designate BASi;


 


WHEREAS, BASi and Pharmasset wish to define
some of the general conditions that will govern the Services to be provided to Pharmasset by BASi;


 


NOW, THEREFORE, in consideration of the
mutual covenants between the parties, and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, it is hereby agreed as follows:


 


		1.	Annual Pricing



 


BASi agrees to provide the Services to Pharmasset
at the pricing specified in the price list (the “Price List”) less the applicable discount rate (the “Discount
Rate”) as set forth in Appendix 1 hereto. The Price List and Discount Rate will become effective at the commencement
of the Agreement and shall remain in effect for twelve (12) months from the Effective Date. The parties agree to review the Price
List and Discount Rate at least thirty (30) days prior to its expiration and, if mutually desired, to amend the same accordingly.
Included as Appendix 2 to this agreement is a listing of projects awarded prior to the execution of this PPA, which includes discounts
provided by BASi in the negotiation and agreement of the projects. Pharmasset and BASi agree that the final pricing to be applied
to these studies will be the Price List amount (prior to discount) less the larger of i) the discount applied in the original
bid, or ii) the discount computed using the contract formula in this agreement.


 


		2.	Specific Studies



 


Upon request, BASi will provide detailed study parameters
and costs, based upon the Price List and Discount Rate, for the relevant Services so requested (each a “Study”) to
Pharmasset for its review and approval. Terms and conditions which will be applicable for each particular Study performed under
this Agreement shall be set forth in a supplemental document (“Study Agreement”) arrived at by mutual negotiations
between the parties, an example of which is attached hereto as Appendix 2. A protocol, mutually acceptable standard operating
procedure, or methodology description for each Study is to be attached to each Study Agreement.


 



    	Page 1 of 4



    	 



    

 





 


		3.	Priority Status



 


BASi agrees to assign a priority status to any Pharmasset
Study and to place the Study in BASi’s schedule such that Pharmasset will be able to meet its timelines and requirements.
Pharmasset agrees to use BASi as its provider of first choice for toxicology studies. Pharmasset shall provide a rolling forecast
of planned studies to BASi. Such forecast shall be used by BASi for planning purposes only and listed studies will not be considered
by BASi as definitive Studies that will ultimately be approved for funding. BASi shall not incur any expenses for studies based
on the forecast. Pharmasset shall only be liable for expenses associated with Studies for which a Study Agreement has been fully
executed.


 


		4.	Debarred Parties



 


BASi certifies that it is not debarred under subsections
306(a) or (b) of the U.S. Federal Food, Drug and Cosmetic Act and that it has not and will not use in any capacity the services
of any person debarred under such law with respect to services to be performed under this Agreement. BASi further certifies that
it will amend this certification as necessary in light of new information and shall notify Pharmasset of such amendment as soon
as possible.


 


		5.	Indemnification and Hold Harmless



 


BASi shall indemnify and hold Pharmasset harmless
from and against any and all losses, costs (including reasonable attorneys’ fees), damages, or injuries to any of BASi’s
Contract Workers, its employees, Pharmasset’s employees or agents or third persons arising directly or indirectly out of
or in the course of performance of the Services under this Agreement caused by or resulting from the negligence of BASi, its employees,
agents or subcontractors. As used herein, Contract Workers will mean persons performing services for BASi who are not employees
of BASi.


 


Pharmasset shall indemnify and hold BASi harmless
from and against any and all losses, costs (including reasonable attorneys’ fees), damages, or injuries to any of Pharmasset’s
employees, BASi’s Contract Workers, its employees or agents during the term of this Agreement caused by or resulting from
the negligence of Pharmasset or its employees.


 


		6.	Confidentiality



 


BASi and its representatives will maintain as secret
and confidential and will not disclose to third parties without prior written permission from Pharmasset any trade secrets and
other confidential information, including data and other information resulting from any Study, (“Confidential Information”)
of Pharmasset gained from discussions or in any other way, including but not limited to descriptions, specifications, product
formulas or bill of materials, production processes and procedures, marketing or manufacturing data, forecasts or information,
supplier sources or agreements, plant layout and plant processes and systems and the like, disclosed or otherwise obtained from
Pharmasset.


 


BASi agrees to maintain the Confidential Information
secret and confidential for a period of ten (10) years following receipt and to only make it available to those Contract Workers
who have a need to know the Confidential Information in order to provide the Services and who are already bound by confidentiality
obligations with respect to the Confidential Information as least as restrictive as those contained herein.


 


The confidentiality obligations above described shall
not apply to Confidential Information which:


 


		(i)	Is already known to BASi at the time of disclosure from sources
                                                               other than from Pharmasset, directly and indirectly;



 


		(ii)	Is or subsequently becomes available to the public, through
                                                                no fault of BASi;



 



    	Page 2 of 4



    	 



    

 





 


		(iii)	Is obtained in good faith from a third party legally entitled
                                                                 to disclose such information, who does not require BAS to keep
                                                                 the information confidential;



 


		(iv)	Is required by law, regulation or governmental order to be
                                                                disclosed, provided that BASi will provide Pharmasset advance
                                                                notice thereof and shall disclose only that part that is strictly
                                                                necessary and legally required.



 


		7.	Applicable Law



 


This Agreement shall be construed according to the
laws of the State of New York


 


		8.	Official Correspondence



 


Any notice or other communication required or permitted
to be made or given to either party pursuant to this Agreement shall be sufficiently made or given effective on the next business
day if sent to such party by telecopy (facsimile) transmission or three (3) business days following transmittal by certified or
registered first class mail as follows:


 


	If to Pharmasset:	If to BASi:
	 	 





	Pharmasset, Inc.	BASi
	303-A College Road East	10424 Middle Mount Vernon Road
	Princeton, NJ 08540	Mount Vernon, IN 47620
	Fax: 609-613-4150	Fax:


 


Correspondence which is directed to Pharmasset and
is related to administrative, financial or scientific matters should be directed to Pharmasset’s Study Administrator who
will be identified on the appropriate Study Agreement;


 


Correspondence which is directed to Pharmasset and
is related to this Agreement should be directed to: General Counsel.


 


Correspondence that is directed to BASi and is related
to scientific matters should be directed to: John Devine.


 


Correspondence that is directed to BASi and is related
to administrative, financial, or contractual matters should be directed to:


 


John Devine


BASi


10424 Middle Mount Vernon Road

Mount Vernon, IN 47620


 


		9.	Term



 


This Agreement shall remain in effect for two (2)
years from the Effective Date unless terminated earlier on mutual written agreement of the parties, or on 90 days’ advance
written notice by either party to the other, or in the event of breach. For purposes of this Agreement, a breach means the failure
of either party to observe any of the terms of this Agreement to a material extent and to remedy the same (where it is capable
of being remedied) within the period specified in a notice given by the aggrieved party to the breaching party calling for remedy,
such period being not less than thirty (30) days.


 



    	Page 3 of 4



    	 



    

 





 


Without prejudice to any other remedy either party
may have against the other for the breach or non-performance of this Agreement, either party may terminate this Agreement immediately
upon the occurrence of any of the following events: 


		a)	Either party being for any reason prevented from or incapable
                                                               of performing its duties hereunder for a continuous period of three
                                                               (3) months;






		b)	Either party becoming insolvent or having a receiver or administrator
                                                               appointed of its assets or execution or distress levied upon its
                                                               assets; or






		c)	An order being made or a resolution being passed for winding-down
                                                               or liquidation of either party (except where any such event is
                                                               only for the purposes of amalgamation with another or reconstruction
                                                               and the resultant company emerging is or agrees to be bound be
                                                               the terms hereof).



 


Termination or expiration of the Agreement shall
not affect the survival and continuing validity of any provision which is expressly or by implication intended to continue in
force after such termination.


 


IN WITNESS WHEREOF, the parties have accepted and agreed upon
this Agreement on the date first set forth above in the opening paragraph.


 


	PHARMASSET, INC.	 	BIOANALYTICAL SYSTEMS, INC.
	 	 	 
	/s/Michael Otto	 	/s/ Michael R. Cox 
	 	 	
	Signature	 	Signature
	 	 	 
	CSO	 	 
	 	 	VP-Finance
	 	 	 
	Title	 	Title
	 	 	 
	7/29/2010	 	 
	 	 	2 Aug 2010
	 	 	 
	Date	 	Date


 



    	Page 4 of 4



    	 



    

 





 


APPENDIX 1


Price List


 


[*]


 


Discount Rate


 


[*]


 



    	Page 1 of 12



    	 



    

 





 


APPENDIX 2


Awarded Quotes


 


[*]


 


Study Designs


 


[*]


 



    	Page 2 of 12



    	 



    

 





 


APPENDIX 3


 


	 	 	 	.
	 	 	Pharmasset, Inc.	 
	Contact:	 	303 A  College Road East	 
	 	Princeton, NJ 08540	Proposal For: Pharmasset, Inc
	 	 	USA	 


 


	 	 	 
	Date:	 	 
	Expires:	 	 
	Client No.:	 	0515
	Quote No.:	 	 
	Currency:	 	USD
	Site:	 	Evansville, IN


 


Sponsor Protocol:


 


We are pleased to provide the following
proposal. Please review the term sheet for complete details and conditions. Scientific conduct of the study and the study costs
will be governed by the final protocol as signed by both parties.


 


	Estimated
    Total Cost:





	Billing Milestones	Percentage





	Acceptance of Agreement	 





	Issuance of Draft Report	 





	Potential Additional Fees
    (not included in total)	Cost
    Per Occurrence





	 


 



    	Page 1 of 4



    	 



    

 


 


 


	Definitions	 
	SPONSOR	A person or other entity who initiates, by provision of financial or other resources, a project and who submits the final
    report to the regulatory agencies.
	 	 
	CONTRACTOR	Bioanalytical Systems, Inc. (BASi), its employees, and Sponsor-agreed subcontractors engaged to perform work on behalf
    of the Sponsor.


 


	Terms	 
	STUDY INITIATION AND

    INVOICE INFORMATION	When you return one copy
        of this fully executed quotation to BASi, we mutually commit to your project. The table above shows the billable milestones
        for this quotation. A tentative start date will not be established without signature execution of this agreement.
        

         

        Upon receipt of the signed quote, BASi will assign
        a Study Director, prepare the protocol and send it to the sponsor for review and approval and establish a tentative starting
        date for the study. The signed protocol, sufficient test material to begin the study and acceptable dose formulation
        methods must be received at BASi not less than 10 working days prior to scheduled study initiation or the starting date
        may postponed to a later date.

         

        Costs incurred as a result of sponsor delays will be
        separate and above the costs shown in the quote (i.e. Animal per diem charges, costs of pre initiation clinical pathology
        tests, etc.).

         

        Invoices will be generated according to the details
        and milestones agreed upon in the table above. Payment will be submitted following receipt by Sponsor of an official invoice
        from Contractor.  Payment terms will be established upon credit approval and denoted on the official invoice.

         

        If a purchase order must be referenced, or if there
        are any other special billing instructions, please include them with the signed quotation.

         

        All invoices will be forwarded to the sponsor’s
        accounts payable office unless different instructions are provided to BASi in writing.

	 	 
	PROTOCOL	BASi standard protocol format will be used unless otherwise requested by the sponsor. Any changes to the study work scope
    will be documented with a protocol amendment to be approved by both parties. If the changes are significant, an amended quotation
    may be required to support the requested changes. If they are minimal then they may be identified as a line item on
    the next scheduled study invoice.
	 	 
	TEST MATERIALS	Certificates of analysis or other sponsor-supplied documents that state the purity, expiration date, and storage conditions
    must accompany sponsor-supplied test materials.  No projects will be authorized to begin until this information is provided. 
    Any part of a study jeopardized by inaccurate preliminary information will be repeated, if necessary, at the sponsor’s
    expense.
	 	 
	EXPEDITED REPORTS	There will be a surcharge equal to 25% of the histopathology charges, report writing and Quality Assurance fees for expediting
    report deadlines described in the original protocol.
	 	 
	QC’D INTERIM DATA TABLE

    OR REPORTS	Study Protocol will specify the report’s
        content as well as the means of reporting the final study data in tables. BASi study reports and table styles will be
        used as the default specification if the sponsor does not identify an alternative.

         

        If you have special reporting formats,
        please let us know prior to signing this term sheet. Planning at the start of a project is essential for the expedient
        and efficient outsourcing. If your report format must differ from our format, we may provide a revised project proposal
        after reviewing your specifications.

         



 



    	Page 2 of 4



    	 



    

 





 


 





	 	Extensive reporting changes required after the project is underway or during the report preparation process will carry a surcharge of 25% of the normal rate for reports and Quality Assurance fees. Such changes include but are not limited to customized data formats, data file conversions, more than two revisions of the draft final report and changes to the final report requested after it has been signed.
	 	 
	 	Six months after issuance of the draft report, if no requested revisions or instructions to finalize have been communicated by the Sponsor, the draft report will be issued as a final report, signed by the Study Director, and submitted to the Sponsor. Any modifications or changes to the draft report requested after issuance of the final report will be performed at additional cost to the Sponsor.
	 	 
	 	The study data will be tabulated from the manually–recorded data records and/or the ToxData/PathData® database and exported into a reporting system. The final BASi report will be created in Microsoft Word.
	 	 
	SAMPLE, SPECIMEN,	BASi will freely provide regulated archive storage of the study specimens, for up to 4 months from the date when the draft final report is sent to the sponsor. Unless otherwise specified by the sponsor, storage of BASi materials will be at controlled room temperature. Refrigerated sample and /or frozen storage is available for samples at an additional cost.
	TISSUE, BLOCK AND SLIDE	 
	STORAGE	An archive storage fee will be assessed after the free storage period.
	 	 
	RAW DATA AND REPORT	The archival storage of the study data at BASi is limited to 5 years. At that time, the sponsor may elect one of the following options:
	STORAGE	 
	 	a)    To authorize BASi to dispose of the data at an additional cost
	 	 
	 	b)    Accept return shipment of the data to the sponsor, at the sponsor’s expense
	 	 
	 	c)    Agree to pay archiving fees to be established by BASi.
	 	 
	PROJECT TERMINATION	Termination notice may be given in writing or verbally with written confirmation to follow within fifteen (15) days.  After receipt of notice, BASi shall (a) terminate the Study in complete compliance with directions received from SPONSOR and (b) perform only such additional work and services as are reasonably necessary or required.  SPONSOR shall pay to BASi within thirty (30) days following receipt by SPONSOR of BASi's appropriate final detailed invoice, an amount equal to (i) all unavoidable costs and expenses reasonably incurred by BASi in connection with the performance and termination of the work, plus (ii) pro rata fees incurred as of the date of termination, less (iii) amounts, if any, previously paid by SPONSOR to BASi pursuant to the provisions of this Agreement; provided, however, that the total of all amounts paid to BASi pursuant to this Agreement shall not exceed the Consideration agreed upon for full performance.







 






    	Page 3 of 4



    	 



    

 





 


If you agree to the terms of this document, please fill out
the information below, sign the proposal, initial each page of the terms sheet, and return a completed copy to attention of the
BASi representative signing the term sheet. The BASi representative may be reached at the phone number and fax number listed below.
BASi looks forward to serving you on this project.


 


Purchase Order: _______________________          
Project Code: _______________________


 


 


	 

        Accepting for:

         

        Signature:

         

        Name:

         

        Title:

         

        Date:

         

        Email:

         

        Fax:

         

        Phone:

         
	 

        Bioanalytical Systems, Inc.

         

        ___________________________

         

        Philip Downing

         

        Director Of Analytical Services

         

          


 


pdowning@basinc.com

         

        812-985-3403

         

        812-985-3400, ext. 125

         
	 

        Accepting for:

         

        Signature:

         

        Name:

         

        Title:

         

        Date:

         

         
	 

        Pharmasset, Inc.

         

        __________________________

         

        __________________________

         

        __________________________

         

        __________________________

         



 



    	Page 4 of 4